Market Overview

Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock


Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage
biopharmaceutical company focused on addressing key mechanisms of tumor
drug resistance, today announced the closing of its previously announced
underwritten public offering of 4,300,000 shares of its common stock at
a public offering price of $40.00 per share for aggregate gross proceeds
of $172 million, before deducting underwriting discounts and commissions
and estimated offering expenses. All of the shares of common stock were
offered by Deciphera.

J.P. Morgan and Piper Jaffray & Co. acted as joint book-running managers
for the offering. Canaccord Genuity LLC and JMP Securities LLC acted as
lead managers, and Nomura Securities International, Inc. and Raymond
James & Associates, Inc. acted as co-managers for the offering.

A registration statement relating to the offering has been filed with
and declared effective by the Securities and Exchange Commission, or
SEC, on June 6, 2018. The offering was made only by means of a
prospectus. A copy of the final prospectus relating to the offering was
filed with the SEC on June 7, 2018 and may be obtained from J.P. Morgan
Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY, 11717, by email at
or by telephone at (866) 803-9204, or Piper Jaffray & Co., 800 Nicollet
Mall, J12S03, Minneapolis, MN, 55402, Attention: Prospectus Department,
by telephone at (800) 747-3924 or by email at

This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company
focused on improving the lives of cancer patients by tackling key
mechanisms of drug resistance that limit the rate and/or durability of
response to existing cancer therapies. Our small molecule drug
candidates are directed against an important family of enzymes called
kinases, known to be directly involved in the growth and spread of many
cancers. We use our deep understanding of kinase biology together with a
proprietary chemistry library to purposefully design compounds that
maintain kinases in a "switched off" or inactivated conformation. These
investigational therapies comprise tumor-targeted agents designed to
address therapeutic resistance causing mutations and immuno-targeted
agents designed to control the activation of immunokinases that suppress
critical immune system regulators, such as macrophages. We have used our
platform to develop a diverse pipeline of tumor-targeted and
immuno-targeted drug candidates designed to improve outcomes for
patients with cancer by improving the quality, rate and/or durability of
their responses to treatment.

Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, as
amended, including, without limitation, statements regarding the
anticipated use of proceeds from the offering, the potential for our
drug candidates to treat cancers and our strategy, business plans and
focus. The words "may," "will," "could," "would," "should," "expect,"
"plan," "anticipate," "intend," "believe," "estimate," "predict,"
"project," "potential," "continue," "target" and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed or
implied by any forward-looking statements contained in this press
release, including, without limitation, the development of our drug
candidates, our ability to successfully demonstrate the efficacy and
safety of our drug candidates and other risks identified in our SEC
filings, including our Registration Statement on Form S-1 filed with the
SEC on June 4, 2018, as amended, our Annual Report on Form 10-K for the
year ended December 31, 2017, our Quarterly Report on Form 10-Q for the
quarter ended March 31, 2018, and subsequent filings with the SEC. We
caution you not to place undue reliance on any forward-looking
statements, which speak only as of the date they are made. We disclaim
any obligation to publicly update or revise any such statements to
reflect any change in expectations or in events, conditions or
circumstances on which any such statements may be based, or that may
affect the likelihood that actual results will differ from those set
forth in the forward-looking statements. Any forward-looking statements
contained in this press release represent our views only as of the date
hereof and should not be relied upon as representing its views as of any
subsequent date. We explicitly disclaim any obligation to update any
forward-looking statements.

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at